Business Description
Poolbeg Pharma PLC
ISIN : GB00BKPG7Z60
Share Class Description:
POLBF: Ordinary SharesTotal Employee Number:
15Description
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.87 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | 7.2 | |||||
3-Year Book Growth Rate | -31.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.94 | |||||
9-Day RSI | 49.58 | |||||
14-Day RSI | 57.31 | |||||
3-1 Month Momentum % | 3.83 | |||||
6-1 Month Momentum % | 46.09 | |||||
12-1 Month Momentum % | 47.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.17 | |||||
Quick Ratio | 6.17 | |||||
Cash Ratio | 5.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.7 | |||||
Shareholder Yield % | -8.35 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -57.32 | |||||
ROA % | -52.49 | |||||
ROIC % | -246.55 | |||||
3-Year ROIIC % | -1676.38 | |||||
ROCE % | -60.35 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.33 | |||||
Price-to-Tangible-Book | 9.19 | |||||
EV-to-EBIT | -7.65 | |||||
EV-to-Forward-EBIT | -7.12 | |||||
EV-to-EBITDA | -7.73 | |||||
EV-to-Forward-EBITDA | -7.12 | |||||
EV-to-FCF | -9.48 | |||||
| Price-to-Net-Current-Asset-Value | 9.19 | |||||
| Price-to-Net-Cash | 9.19 | |||||
Earnings Yield (Greenblatt) % | -13.07 | |||||
FCF Yield % | -9.03 |
GF Valueâ„¢
Poolbeg Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Poolbeg Pharma PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-29 | In 96 days | ||
| General meeting for 2025 | 2026-06-09 11:00 | 0.12 (+0.00%) | ||
| Annual report for 2025 | 2026-05-07 | 0.06 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-28 | 0.06 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-29 | 0.04 (+0.00%) | ||
| General meeting for 2024 | 2025-06-23 12:00 | 0.04 (+0.00%) | ||
| Annual report for 2024 | 2025-05-27 | 0.04 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-05-20 | 0.12 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-18 | 0.15 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:POLBF
No articles.
Press Release
Articles on Poolbeg Pharma PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers